RxDoctor Payments Data

Marissa Takase, MD

Internal Medicine · Honolulu, HINPI 1336536168

Payments from drug & device makers

$7,166in general payments, 2019–2025

Across 406 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$786
  • Boehringer Ingelheim$699
  • Amarin Pharma, Inc.$654
  • Lilly USA, LLC$647
  • GSK$555
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$7,148100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,166 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$99,491
Medicare patients
352
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$126,299
TrulicityDulaglutide37$65,739
EliquisApixaban45$60,862
RybelsusSemaglutide22$54,303
JanuviaSitagliptin Phosphate30$35,275
FarxigaDapagliflozin Propanediol21$32,630
OzempicSemaglutide14$31,623
GemtesaVibegron24$30,920
MounjaroTirzepatide18$28,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,318
JanumetSitagliptin Phos/Metformin Hcl26$22,776
Atorvastatin Calcium433$15,801
VascepaIcosapent Ethyl19$13,253
Rosuvastatin Calcium202$11,460
EdarbiAzilsartan Medoxomil16$10,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$699$126,29994 claims
Lilly USA, LLCTrulicity, Mounjaro$647$94,27055 claims
Novo NordiskRybelsus, Ozempic$786$85,92536 claims
PfizerEliquis$306$60,86245 claims
MerckJanuvia, Janumet$205$58,05056 claims
AstraZenecaFarxiga, Symbicort$417$36,93732 claims
GSKTrelegy Ellipta, Breo Ellipta$555$32,52341 claims
Sumitomo Pharma America, Inc.Gemtesa$24$30,92024 claims
Arbor Pharmaceuticals, Inc.Edarbi$14$10,92416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →